NT219 found to suppress cancer stem cells that promote drug resistance to KRAS G12C and KRAS G12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness... Read More

Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing... Read More

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023. “Our two lead oncology candidates,... Read More

NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune... Read More

NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a Scientific Advisory Board (SAB)... Read More

REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the... Read More

Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the... Read More

This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has... Read More

Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1 /2 Do s e Escalation Study Patients ’ E nrollment in the Phase 2 Randomized CM24 Pancreatic Cancer T rial A head of T imelines C ash R unway Extended to 2H 2025 through Recent Financing REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing... Read More

New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the China National... Read More

REHOVOT, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering of 4,347,827 of the Company’s American Depositary... Read More

REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 4,347,827 of the Company’s American... Read More

REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today reported new biomarker data for its lead oncology drug, CM24, a first-in-class anti-CEACAM1 monoclonal antibody. Data were... Read More

Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial response NT219 exposure at the highest dose level reaching human equivalent dose for efficacy based on animal models Target engagement was confirmed in patients’ tissue biopsies Phase 2 study of NT219 in combination with cetuximab in 2L SCCHN, is... Read More

REHOVOT, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present a poster titled: “Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced... Read More

Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 study Clinical data from both studies expected in the coming months Cash runway extended into H1 2025 REHOVOT, Israel, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the... Read More

Purple’s innovative immuno-oncology, chemotherapy-free regimen reports encouraging Overall Survival data in 3 rd line PDAC patients Randomized Phase 2 study is enrolling as expected with initial Phase 2 data expected by the end of 2023 REHOVOT, Israel, July 11, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies... Read More

Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, May 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and... Read More

Scientific Advisory Board inaugurates new KOL support structure for Purple Biotech Three advisors bring expertise as researchers, oncologists and academicians REHOVOT, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment... Read More

New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune... Read More

REHOVOT, Israel, April 18, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome tumor immune evasion and drug resistance, today announced that Dr. Amir Horowitz, Assistant Professor of Oncological Sciences, Precision... Read More

Board of Directors appoints Isaac Israel, Board member and former CEO, as acting CEO Company’s business plan and clinical development programs continue as planned REHOVOT, Israel, March 24, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor... Read More

Reduction in neutrophil extracellular traps (NETs) markers Potential association between patient survival and CEACAM1 positive lymphocytes REHOVOT, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment (TME) to overcome... Read More

REHOVOT, Israel, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in the randomized part of the open label Phase 2... Read More

Expands pipeline with acquisition of new tri-specific antibodies Data readouts for two lead clinical programs expected in 2023 REHOVOT, Israel, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion... Read More

Immunorizon’s lead compound targets 5T4 antigen and conditionally activates T cells and natural killer (NK) cells Conditional activation of T cells is designed to provide a wide therapeutic index for the compound REHOVOT, Israel, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor... Read More

REHOVOT, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced a research collaboration with Mor Research Applications (Mor), the technology transfer... Read More